The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy
Not available.
Saved in:
Main Authors: | Jinlan Long, Shufeng Xie, Wenjie Zhang, Weiyu Dou, Yixin Wang, Ruiheng Wang, Han Liu, Zhenshu Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-01-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/11912 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01) -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01) -
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
by: Gohar S. Manzar, et al.
Published: (2025-01-01) -
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
by: Yelei Guo, et al.
Published: (2016-01-01) -
Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells
by: Pengju Wang, et al.
Published: (2025-01-01)